The Trefoil Protein TFF1 is Bound to MUC5AC in Human Gastric Mucosa

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2004 Aug 4

PMID 15289936

Citations 33

Authors

M-H Ruchaud-Sparagano

B R Westley

F E B May

Affiliations

Soon will be listed here.

Abstract

The trefoil protein TFF1 is expressed principally in the superficial cells of the gastric mucosa. It is a small protein and forms homo- and hetero-dimers via a disulphide bond through Cys58 which is located three amino acids from the C terminus. TFF1 is co-expressed with the secreted mucin MUC5AC in superficial cells of the gastric mucosa suggesting that it could be involved in the packaging or function of gastric mucus. We have previously shown that TFF1 co-sediments with mucin glycoproteins on caesium chloride gradients. To extend this observation we have now used gel filtration under physiological conditions, immunoprecipitation and Western transfer analysis to characterise the interaction of TFF1 with gastric mucin glycoproteins. We show that TFF1 co-elutes with MUC5AC but not MUC6 on gel filtration and that immunoprecipitation and Western transfer analysis confirms that TFF1 interacts with MUC5AC. We also demonstrate that the TFF1 dimer is the predominant molecular form bound to MUC5AC. Salt and chelators of divalent cations such as EDTA and EGTA disrupted the TFF1- MUC5AC interaction and increased the degradation of MUC5AC, whereas calcium increased the amount of TFF1 bound to MUC5AC. These data support the contention that TFF1 is pivotal in the packaging and function of human gastric mucosa.

Citing Articles

Expression of Trefoil Factor 1 (TFF1) in Cancer: A Tissue Microarray Study Involving 18,878 Tumors.

Lutz F, Han S, Buyucek S, Moller K, Viehweger F, Schlichter R Diagnostics (Basel). 2024; 14(19).

PMID: 39410561 PMC: 11475926. DOI: 10.3390/diagnostics14192157.

Soluble Human Lectins at the Host-Microbe Interface.

Peiffer A, Dugan A, Kiessling L Annu Rev Biochem. 2024; 93(1):565-601.

PMID: 38640018 PMC: 11296910. DOI: 10.1146/annurev-biochem-062917-012322.

Ion mobility-tandem mass spectrometry of mucin-type O-glycans.

Bechtella L, Chunsheng J, Fentker K, Erturk G, Safferthal M, Polewski L Nat Commun. 2024; 15(1):2611.

PMID: 38521783 PMC: 10960840. DOI: 10.1038/s41467-024-46825-4.

An Exploratory Data Analysis from Ovine and Bovine RNA-Seq Identifies Pathways and Key Genes Related to Cervical Dilatation.

Goncalves J, Ferraz J, Meirelles F, Nociti R, Oliveira M Animals (Basel). 2023; 13(13).

PMID: 37443850 PMC: 10339884. DOI: 10.3390/ani13132052.

Diagnostic utility of trefoil factor families for the early detection of lung cancer and their correlation with tissue expression.

Minegishi K, Dobashi Y, Koyama T, Ishibashi Y, Furuya M, Tsubochi H Oncol Lett. 2023; 25(4):139.

PMID: 36909373 PMC: 9996639. DOI: 10.3892/ol.2023.13725.

References

Levine , HOCHMAN . Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock. J Thromb Thrombolysis. 1995; 2(1):11-20. DOI: 10.1007/BF01063156. View

Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R . A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008; 52(19):1584-8. DOI: 10.1016/j.jacc.2008.05.065. View

Cooper H, Najafi A, Ghafourian K, Paixao A, Aljaabari M, Iantorno M . Diagnosis of cardiogenic shock without the use of a pulmonary artery catheter. Eur Heart J Acute Cardiovasc Care. 2014; 4(1):88-95. DOI: 10.1177/2048872614534564. View

Cheng J, den Uil C, Hoeks S, van der Ent M, Jewbali L, van Domburg R . Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009; 30(17):2102-8. DOI: 10.1093/eurheartj/ehp292. View

De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C . Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362(9):779-89. DOI: 10.1056/NEJMoa0907118. View

Thiele H, Sick P, Boudriot E, Diederich K, Hambrecht R, Niebauer J . Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005; 26(13):1276-83. DOI: 10.1093/eurheartj/ehi161. View

Hochman J, Sleeper L, WEBB J, Sanborn T, White H, Talley J . Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999; 341(9):625-34. DOI: 10.1056/NEJM199908263410901. View

van Diepen S, Reynolds H, Stebbins A, Lopes R, Dzavik V, Ruzyllo W . Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Crit Care Med. 2013; 42(2):281-8. DOI: 10.1097/CCM.0b013e31829f6242. View

Steg P, van t Hof A, Hamm C, Clemmensen P, Lapostolle F, Coste P . Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23):2207-17. DOI: 10.1056/NEJMoa1311096. View

10.

Jeger R, Urban P, Harkness S, Tseng C, Stauffer J, Lejemtel T . Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials. Acute Card Care. 2011; 13(1):14-20. PMC: 4224032. DOI: 10.3109/17482941.2010.538696. View

11.

Thiele H, Schuler G, Neumann F, Hausleiter J, Olbrich H, Schwarz B . Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J. 2012; 163(6):938-45. DOI: 10.1016/j.ahj.2012.03.012. View

12.

Goldberg R, Spencer F, Gore J, Lessard D, Yarzebski J . Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation. 2009; 119(9):1211-9. PMC: 2730832. DOI: 10.1161/CIRCULATIONAHA.108.814947. View

13.

Sheu J, Tsai T, Lee F, Fang H, Sun C, Leu S . Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med. 2010; 38(9):1810-7. DOI: 10.1097/CCM.0b013e3181e8acf7. View

14.

Hasdai D, Harrington R, Hochman J, Califf R, Battler A, Box J . Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol. 2000; 36(3):685-92. DOI: 10.1016/s0735-1097(00)00814-7. View

15.

White H, Assmann S, Sanborn T, Jacobs A, Webb J, Sleeper L . Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.... Circulation. 2005; 112(13):1992-2001. DOI: 10.1161/CIRCULATIONAHA.105.540948. View

16.

Prondzinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter J . Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med. 2009; 38(1):152-60. DOI: 10.1097/CCM.0b013e3181b78671. View

17.

Asfar P, Meziani F, Hamel J, Grelon F, Megarbane B, Anguel N . High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014; 370(17):1583-93. DOI: 10.1056/NEJMoa1312173. View

18.

Bonello L, De Labriolle A, Roy P, Steinberg D, Pinto Slottow T, Xue Z . Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock. Am J Cardiol. 2008; 102(3):287-91. DOI: 10.1016/j.amjcard.2008.03.052. View

19.

Thiele H, Zeymer U, Neumann F, Ferenc M, Olbrich H, Hausleiter J . Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013; 382(9905):1638-45. DOI: 10.1016/S0140-6736(13)61783-3. View

20.

Sakr Y, Reinhart K, Vincent J, Sprung C, Moreno R, Ranieri V . Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med. 2006; 34(3):589-97. DOI: 10.1097/01.CCM.0000201896.45809.E3. View